• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Erythroid Enhancer of BCL11A Gene May Determine Fetal Hemoglobin Levels

October 25, 2013

A study published in the journal Science reveals that an erythroid enhancer of the BCL11A gene may be essential for determining fetal hemoglobin (HbF) levels. Researchers characterized common genetic variations in the BCL11A gene that were associated with elevated HbF levels, showing that these polymorphisms resided within a tissue- and developmental stage-specific enhancer. Genome engineering demonstrated that the enhancer is required for BCL11A expression within erythroid, but not within B-lymphoid cells. The BCL11A enhancer may serve as a potential genome-specific target to treat β-hemoglobinopathies.

 

Reference

1.    Bauer DE, Kamran SC, Lessard S, Xu J, Fujiwara Y, Lin C, Shao Z, Canver MC, Smith EC, Pinello L, Sabo PJ, Vierstra J, Voit RA, Yuan GC, Porteus MH, Stamatoyannopoulos JA, Lettre G, Orkin SH. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 2013;342: 253-7

Filed Under

  • News
  • Special Transfusion Situations

Recommended

  • Liquid Plasma Acceptable for Severe Trauma Patients with Major Bleeding

  • National Survey Finds Stable Adverse Transfusion Reaction Rate in the U.S.

  • The Role of Osteopontin in Murine TRALI

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Double-knotting Blood Storage Bag Tubing Reduces Contamination

  • Costs of Type & Screen and Crossmatch Laboratory Tests for RBCs Higher in U.S. Compared to U.K.

  • Gene Editing of HBG1 and HBG2 Promotors to Treat β-Thalassemia and Sickle Cell Disease

  • Jehovah’s Witness Governing Body Allows Autologous Transfusions

    Question of the Day

    Copyright © 2026 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley